INBP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INBP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Integrated Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $1.635. Integrated Biopharma's 10-Year median PS Ratio is 0.1284. Therefore, the Median PS Value for today is $0.21.
As of today (2024-12-15), Integrated Biopharma's share price is $0.318. Integrated Biopharma's Median PS Value is $0.21. Therefore, Integrated Biopharma's Price to Median PS Value for today is 1.52.
The historical rank and industry rank for Integrated Biopharma's Median PS Value or its related term are showing as below:
During the past 13 years, the highest Price to Median PS Value of Integrated Biopharma was 6.12. The lowest was 0.44. And the median was 1.26.
The historical data trend for Integrated Biopharma's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Biopharma Annual Data | |||||||||||||||||||||
Trend | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | Jun24 | |||||||||||
Median PS Value | Get a 7-Day Free Trial | 0.15 | 0.19 | 0.19 | 0.20 | 0.21 |
Integrated Biopharma Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Median PS Value | Get a 7-Day Free Trial | 0.22 | 0.23 | 0.22 | 0.21 | 0.21 |
For the Packaged Foods subindustry, Integrated Biopharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Integrated Biopharma's Price-to-Median-PS-Value falls into.
Integrated Biopharma's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 1.635 | * | 0.1284 | |
= | 0.21 |
10-Year Median PS Ratio is 0.1284.
Integrated Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.635.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Biopharma (OTCPK:INBP) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Integrated Biopharma's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 0.318 | / | 0.21 | |
= | 1.51 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Integrated Biopharma's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Damon Desantis | director | 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431 |
William H. Milmoe | director, 10 percent owner | 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431 |
Joseph Laplaca | director | 72 EUGENE DRIVE, MONTVILLE NJ 07045 |
E Gerald Kay | director, 10 percent owner, officer: Chairman and CEO | C/O 225 LONG AVENUE, HILLSIDE NJ 07205 |
Bradley J Hoecker | director | STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Jeffrey R Leach | director, officer: President and CEO | |
Glenn Chang | director | C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711 |
Vidadi Yusibov | director | C/O IBIOPHARMA, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711 |
Cd Financial, Llc | 10 percent owner | 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431 |
Kay Riva | director, officer: Vice President | C/O 225 LONG AVENUE, HILLSIDE NJ 07205 |
Christina Kay | director, officer: Vive President | C/O 225 LONG AVENUE, HILLSIDE NJ 07205 |
Robert Canarick | director | C/O INTEGRATED BIOPHARMA, INC., 201 ROUTE 22, HILLSIDE NJ 07205 |
Robert Kay | director | C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711 |
Dina Masi | officer: Chief Financial Officer | 14 LEXINGTON WAY, LONG VALLEY NJ 07853 |
Carl Desantis | director, 10 percent owner | C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 02-12-2021
By [email protected] [email protected] • 05-15-2019
By [email protected] [email protected] • 05-14-2020
By ACCESSWIRE ACCESSWIRE • 09-24-2020
By [email protected] [email protected] • 09-16-2019
By [email protected] [email protected] • 02-12-2020
By ACCESSWIRE ACCESSWIRE • 11-13-2020
By [email protected] [email protected] • 11-13-2019
By ACCESSWIRE ACCESSWIRE • 11-11-2021
By ACCESSWIRE AccessWire • 05-06-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.